Confo Therapeutics is a drug discovery company building a unique pipeline of GPCR targeted therapeutics addressing unmet medical need. The company was founded in 2015 as a spin-off from the VUB and VIB and capitalizes on the ConfoBody™ technology developed by Prof. Jan Steyaert at VIB Structural Biology Research Center, Vrije Universiteit Brussel.
ConfoBodies are camel single domain antibodies that stabilize distinct druggable conformers of flexible protein targets and reveal previously inaccessible structural features. Confo Therapeutics uses these ConfoBody™-stabilized functional conformations of GPCRs as a superior starting point for drug discovery empowering the discovery of novel agonists for better therapeutic intervention.
Milestones
- 2015: founded by the VUB and VIB
- 2017: drug discovery collaboration with Roche
- 2019: Confo raises €30 million in Series A financing and €1.7 million grant from VLAIO to target an orphan indication- drug discovery collaboration with DyNAbind
- 2022: Confo Therapeutics doses first subjects in Phase 1 clinical trial of CFTX-1554 for the treatment of neuropathic pain
- 2024: EUR 60M Series B Financing to advance pipeline of Novel GPCR-Modulating Therapies into clinical development and €1.6 million VLAIO Grant Supporting Drug Discovery & Development in Endocrine and Metabolic Diseases
Contact
Confo Therapeutics
Cedric Ververken, CEO
Technologiepark-Zwijnaarde 30
B - 9052 Ghent
Belgium
